The colonization of Multi-Drug-Resistant Organisms (MDRO) are an increasing problem in the health care system and have a serious impact on the community. This colonization has to be avoided at all cost to prevent severe problems such as infection, especially prior to surgical interventions, in catheterised patients, or in immunosuppressed patients.
Several clinical studies have shown that cleansing with antimicrobial cleansers (e.g. with Prontoderm®) the night and the morning before the planned operation can reduce the incidence of post-operative surgical site infections (SSI).*
*Source Zywiel MB et al. Int Orthop. 2011 Jul; 35(7):1001–1006.
New Study: Integrated MRSA management
In June 2016 the study from Jahn et al "Integrated MRSA management (IMM) with prolonged decolonization treatment after hospital discharge is effective: a single-centre, non-randomized, open-label trial" was published. The conclusion is very promising:
"The IMM strategy offers an MRSA decolonization protocol that is feasible in the domestic setting and is equally effective compared with inpatient decolonization treatment when hospital lenth of stay (LOS) is long enough to complete the treatment. Moreover, for patients with average LOS, decolonization rates obtained with IMM are significantly higher than for in-hospital treatment. IMM is a promising concept to improve decolonization rates of MRSA-carriers for patients who leave the hospital before decolonization is completed."
The percentage of resistant organisms has increased in hospital settings over the past years. Approximately 15% of patients who acquired Methicillin-resistant Staphylococcus aureus (MRSA) developed a subsequent infection.
Prontoderm is able to inhibit MDRO growth, spread or transmission. The efficacy for MRSA, ESBL/ESCR and VRE are proven by EN13727. Furthermore Prontoderm shows a leave on antimicrobial barrier effect for up to 24 hours.